Sidley is representing Venus Medtech (Hangzhou) Inc., a leading, innovative Chinese structural heart disease treatment company, in the acquisition of Cardiovalve Ltd., an Israel-based, pioneering transcatheter mitral and tricuspid valve treatment company.
Venus Medtech will acquire 100% of the equity of Cardiovalve for up to US$300 million. The deal is expected to expand Venus Medtech’s innovative product layout of mitral valve replacement and tricuspid valve replacement, further enhance product pipeline, and accelerate its internationalization.
This groundbreaking transaction exemplifies Sidley’s ability to handle clients’ most complex, multi-jurisdictional life sciences matters.
The Sidley team is led by Frank Rahmani (Global Life Sciences) and Josh DuClos (M&A), and includes Ruchun Ji, Ellen Hunter, and BinQuan Zhuang (M&A), as well as Josh Hofheimer, Jean Qiu (Technology and IP Transactions), Torrey Cope, Maurits Lugard, Michele Tagliaferri, Olivier Goarnisson (Healthcare), Samuel Tiu (IP Litigation), Francesca Blythe, and Sheri Porath Rockwell (Privacy and Cybersecurity).
